Concert pharmaceuticals, inc. (CNCE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue:
License and research and development revenue

7

-

-

-

1,005

-

-

-

-

-

143,844

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License and research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

20

-

26

71

56

305

1,709

3,254

1,306

1,310

2,418

1,235

1,613

1,413

681

17,441

3,873

Other revenue (Note 14 and Note 13)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

50,155

-

-

0

-

-

-

-

-

-

Milestone revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,000

-

-

0

0

0

2,000

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26

71

56

10,305

1,709

53,409

1,306

1,310

4,418

1,235

1,613

1,413

681

17,441

5,873

Operating expenses:
Research and development

13,986

16,019

13,511

14,496

15,790

14,600

11,031

8,862

8,656

7,565

7,136

7,285

8,237

8,660

8,054

9,816

10,453

6,386

7,135

8,420

6,944

7,068

8,569

6,243

5,594

5,330

5,668

5,753

5,039

General and administrative

4,672

4,947

4,742

4,978

5,609

5,476

6,320

5,514

5,630

5,184

4,875

5,707

5,253

3,513

3,440

3,828

3,577

3,256

3,268

3,299

3,233

2,987

3,457

2,718

2,538

1,662

2,129

2,273

1,964

Total operating expenses

18,658

20,966

18,253

19,474

21,399

20,076

17,351

14,376

14,286

12,749

12,011

12,992

13,490

12,173

11,494

13,644

14,030

9,642

10,403

11,719

10,177

10,055

12,026

8,961

8,132

6,992

7,797

8,026

7,003

Loss from operations

-18,651

-20,953

-18,243

-19,425

-20,394

-20,063

-17,340

-14,374

-3,807

-12,737

131,833

-12,977

-13,470

-12,152

-11,468

-13,573

-13,974

663

-8,694

41,690

-8,871

-8,745

-7,608

-7,726

-6,519

-5,579

-7,116

9,415

-1,130

Investment income

563

513

724

883

867

784

703

660

640

594

450

155

137

109

112

132

94

44

37

26

17

14

15

16

4

4

3

3

11

Interest and other expense

-

-

-

-

-

-

-

-

-

-

609

205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-58

-103

-148

-196

-239

-280

-435

-340

-14

-653

-660

Gain (Loss) on Extinguishment of Debt

-

-

-

-

-

-

-

-

-

-

-1,432

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on marketable equity securities

-2,389

-59

334

-126

-2,299

-1,567

-732

669

-1,296

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income (Loss) before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,356

-13,441

-

-

-

-

-

-

-7,832

-7,990

-

-

-

-

-

Loss before income taxes

-

-

-17,185

-18,668

-

-

-17,369

-13,045

-

-

130,242

-13,027

-

-

-

-

-

-

-8,715

41,613

-

-

-

-

-

-

-

-

-

Income Tax Expense (Benefit)

-

-

0

0

-

-

18

280

-

-

2,177

0

-

-

0

-

-

-

-161

567

-

-

0

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-20,477

-20,487

-17,185

-18,668

-21,826

-20,849

-17,387

-13,325

-4,463

-6,066

128,065

-13,027

-13,333

-

-11,356

-

-13,880

684

-8,554

41,046

-9,002

-8,927

-7,832

-7,990

-6,950

-5,915

-7,127

8,765

-1,779

Other comprehensive income:
Other comprehensive income:
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

523

4

-39

44

97

104

87

154

-75

-340

-23

-10

-27

-40

-10

12

49

-38

33

-19

20

-29

4

15

-8

-3

7

-3

-1

Comprehensive loss

-19,954

-20,483

-17,224

-18,624

-21,729

-20,745

-17,300

-13,171

-4,538

-6,406

128,042

-13,037

-13,360

-12,083

-11,366

-13,429

-13,831

-

-8,521

41,027

-8,982

-

-7,828

-7,975

-6,958

-

-

-

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,918

-7,120

8,762

-1,780

Net (loss) income

-20,477

-20,487

-17,185

-18,668

-21,826

-20,849

-17,387

-13,325

-4,463

-6,066

128,065

-13,027

-13,333

-

-11,356

-

-13,880

684

-8,554

41,046

-9,002

-8,927

-7,832

-7,990

-6,950

-5,915

-7,127

8,765

-1,779

Accretion on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

55

99

100

99

98

Undistributed earnings applicable to participating preferred shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,666

-

Net Income (Loss) Available to Common Stockholders, Basic

-

-

-

-

-

-

-

-

-

-

127,324

-

-

-

-11,356

-

-

-

-

-

-

-

-

-

-

2,652

-7,227

0

-1,877

Net Income (Loss) Available to Common Stockholders, Diluted

-

-

-

-

-

-

-

-

-

-

127,347

-

-

-

-11,356

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)

-0.70

-0.86

-0.72

-0.78

-0.93

-0.90

-0.74

-0.57

-0.19

-

-

-0.58

-0.60

-

-

-0.60

-0.63

-

-

-

-0.48

-

-

-

-0.76

-

-5.59

0.00

-1.46

Net (loss) income applicable to common stockholdersbasic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,832

-7,990

-7,005

-

-

-

-

Earnings Per Share, Basic

-

-

-

-

-

-

-

-

-

-

5.61

-

-

-

-0.51

-

-

-

-0.39

1.89

-

-

-0.43

-0.45

-

-

-

-

-

Earnings Per Share, Diluted

-

-

-

-

-

-

-

-

-

-

5.44

-

-

-

-0.51

-

-

-

-0.39

1.80

-

-

-0.43

-0.45

-

-

-

-

-

Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares)

29,110

23,855

23,807

23,790

23,508

23,434

23,421

23,402

23,223

-

-

22,579

22,377

-

-

22,217

22,198

-

-

-

18,726

-

-

-

9,188

-

1,293

-

1,290

Weighted Average Number of Shares Outstanding, Basic

-

-

-

-

-

-

-

-

-

-

22,694

-

-

-

22,229

-

-

-

21,949

21,762

-

-

18,098

17,937

-

-

-

1,290

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

-

-

-

-

-

-

-

-

23,421

-

-

-

22,229

-

-

-

21,949

22,850

-

-

18,098

17,937

-

-

-

2,638

-

License and research and development revenue
Total revenue

-

-

10

49

-

13

11

2

10,479

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-